The highest percentages of patients with HBsAg loss were observed in the groups that received xalnesiran plus an immunomodulator. The most frequent grade 3 or 4 adverse event was elevated ALT.

loss – defined as HBsAg levels below the lower limit of quantitation (Two participants also met the criteria for functional cure, meaning that results demonstrated sustained HBsAg loss and ...